Avid Bioservices Moves Forward with Acquisition Plans
Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization, has reached a significant milestone in its upcoming acquisition by GHO Capital Partners LLP and Ampersand Capital Partners. The expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act is a pivotal step toward completing this deal.
Company's Vision and Commitment
Nick Green, the president and CEO of Avid, expressed optimism following this announcement. He stated, "With this milestone behind us, we are one step closer to completing this transaction and delivering significant, immediate and certain value to our stockholders." His commitment emphasizes that Avid believes this move is beneficial for its shareholders, prompting them to vote in favor of the acquisition.
Anticipated Timeline for Completion
The completion of the acquisition transaction is expected to take place during the first quarter of 2025, pending the approval of Avid's stockholders and the fulfillment of standard closing conditions. This timeline reflects Avid's preparedness and eagerness to embark on a new chapter in its journey.
About Avid Bioservices
Avid Bioservices specializes in the development and CGMP manufacturing of biologics. With over 30 years of experience, the firm provides a wide range of services that encompass everything from drug substance manufacturing to regulatory submission support. The transition to a comprehensive service model is aimed at enhancing clinical and commercial manufacturing efficiency for the biotechnology and biopharmaceutical industries.
Advisory Team Supporting the Transaction
For this acquisition, Moelis & Company LLC is serving as the exclusive financial advisor for Avid, while Cooley LLP is providing legal counsel. Their roles are crucial in ensuring that the process moves smoothly and complies with regulatory requirements.
Important Information for Shareholders
As part of the acquisition process, Avid Bioservices has filed a proxy statement with the U.S. Securities and Exchange Commission (SEC) ahead of a special meeting for its stockholders. The company urges stockholders to review the proxy statement thoroughly in order to understand the details of the proposed transaction.
Implications of the Acquisition
This acquisition is seen as a strategic move that enhances Avid's potential and market position within the biologics sector. By joining forces with GHO and Ampersand, Avid aims to leverage combined expertise and resources to drive growth and innovation in its manufacturing processes.
What’s Next for Avid Bioservices
The upcoming months will be crucial for Avid as it works to finalize its acquisition. The focus will be on ensuring alignment with stakeholders and maintaining operational efficiency during this transition. The successful completion of this deal could significantly bolster Avid’s growth trajectory and enhance shareholder value.
Frequently Asked Questions
What is the significance of the Hart-Scott-Rodino waiting period expiration?
The expiration of this waiting period is a regulatory step that allows Avid to move forward with its acquisition by GHO and Ampersand without further antitrust scrutiny.
When is the expected completion of the acquisition?
The acquisition is expected to complete in the first quarter of 2025, pending stockholder approval and other conditions.
Who are the advisors involved in the acquisition process?
Moelis & Company LLC is acting as the financial advisor, while Cooley LLP serves as the legal counsel for Avid Bioservices.
Why should stockholders vote for the transaction?
Voting in favor of the transaction is viewed as a way to secure immediate and substantial value for stockholders as Avid transitions into a potentially more robust operational phase.
What services does Avid offer?
Avid offers a range of services for biologics manufacturing, including CGMP clinical and commercial manufacturing, process development, and regulatory support.
